Compare Medpace Holdings Inc (MEDP) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Quantum Computing Inc — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Quantum Computing Inc trades at $7.46 (market cap $1.69B). The key difference: Medpace Holdings Inc is far larger — about 10× Quantum Computing Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Quantum Computing Inc for 25 Days on average.
| MEDP | QUBT | |
|---|---|---|
Market Cap | $16.82B | $1.69B |
Volume | 223,093 | 7,991,522 |
Sector | Health | Technology |
52-Week High | $630.19 | $21.78 |
52-Week Low | $393.42 | $6.31 |
Typical Hold Time | 14 Days | 25 Days |
Enterprise Value | $16.44B | $753.24M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Quantum Computing Inc. (QUBT) trades at $7.43, down 2.49% today, with a bearish technical signal despite bullish oscillators. The company shows explosive revenue growth from $682K in 2025 to $10M projected for 2026, but remains deeply unprofitable with a -152.45% net income margin. Recent developments include the Dirac-3S quantum system launch and a $42.5M backlog, though rising expenses and shareholder litigation create headwinds.
QUBT offers speculative growth potential in quantum computing with strong analyst support (75% buy rating, $17.33 target) but faces significant execution risks. The stock's appeal hinges on commercializing quantum technology amid persistent losses and competitive threats, requiring careful risk assessment by growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
